PET scan tracer to spot hormone-producing adrenal tumors
Tests a PET scan tracer in adults with adrenal tumors and excess hormones.
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 80 people, planned
- Started
- 23 Sept 2024
- Expected to end
- 1 Apr 2030
- Type of study
- Interventional
- Treatments tested
- [68Ga]Ga-PentixaFor
- Record updated
- 22 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with too much of the adrenal hormones aldosterone or cortisol. They will have one PET scan with the tracer [68Ga]Ga-PentixaFor.
- Age
- 18 years and older (up to 120 Years).
- Sex
- All sexes can join.
- Disease stage
- One of these: one or more adrenal masses on CT and/or MRI with too much aldosterone; or ACTH-independent hypercortisolism (too much cortisol not driven by ACTH), with or without adrenal masses; or a history of ACTH-dependent hypercortisolism, with or without enlarged adrenal glands. People must be able to do daily activities (ECOG performance status <= 2).
- Earlier treatment
- People must also be enrolled in study 19-DK-0066, 09-C-0242, 18-CH-0031 or a similar NIH trial.
- Biomarker or test result
- Blood or urine tests showing too much aldosterone or cortisol, as described above.
Main reasons for not taking part
- Positive pregnancy test at screening.
- Uncontrolled other illness or social situation that would make it hard to follow the study.
- Cannot have an MRI and CT.
- Not willing to use effective birth control for two weeks before and one week after the scan.
The registry criteria, word for word
Show all 11 criteriaShow less
Who cannot take part
- Uncontrolled intercurrent illness or social situations based on the review of medical history that would limit compliance with study requirements
- Positive beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test performed in females of childbearing potential at screening
- Contraindications to having an MRI and CT
Other criteria
- INCLUSION CRITERIA:
- Must have any of the following:; one or more adrenal masses on CT and/or MRI and biochemical evidence of excess aldosterone; OR; --ACTH-independent hypercortisolism, with or without adrenal masses on CT and/or MRI; OR
- history of ACTH-dependent hypercortisolism (with or without adrenal enlargement)
- Co-enrollment in 19-DK-0066, 09-C-0242, 18-CH-0031 or a similar NIH trial
- Age >=18 years
- ECOG performance status <= 2
- Women of child-bearing potential (WOCBP) and men must agree to use an effective contraception (barrier, hormonal, intrauterine device [IUD], surgical sterilization, abstinence) for two weeks prior to [68Ga]Ga-PentixaFor scan and for one week after the [68Ga]Ga-PentixaFor scan; Breastfeeding should be discontinued for one week after the [68Ga]Ga-PentixaFor scan; Men must agree not to donate sperm for one week after the [68Ga]Ga-PentixaFor scan
- Participants must be able to understand and willing to sign a written informed consent document
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 120 years old?
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: National Cancer Institute Referral OfficeTaking people
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
The adrenal glands are 2 small organs that sit on top of each kidney. They release hormones; these are chemicals that control how the body works. Tumors on or outside the adrenal glands are called functional if they release hormones; they are called nonfunctional if they do not. Doctors who treat adrenal tumors need to know which type a person has. Researchers want to find better ways to learn whether an adrenal tumor is functional.
Objective:
To see if a new radioactive tracer ([68Ga]Ga-PentixaFor) can make it easier to identify functional adrenal tumors with positron emission tomography (PET) scans.
Eligibility:
People aged 18 years and older with 1 or more adrenal tumors. They must have increased levels of the hormones aldosterone or cortisol. They must also be enrolled in at least 1 other related NIH study (protocols 19-DK-0066, 18-CH-0031, or 09-C-0242).
Design:
Participants will be screened. They may have imaging scans. Their ability to perform normal activities will be reviewed.
Participants will have one PET scan with the study tracer.
The tracer will be given through a tube attached to a needle inserted into a vein. Participants will receive the tracer 1 hour before the scan. They will lie still on a bed while a machine captures images of the inside of their body. The scan will take 45 to 90 minutes.
Participants heart rate, blood pressure, and rate of breathing will be checked before, during, and after the scan.
Participants will have a follow-up visit 3 days after their scan. This visit can be by phone, email, or in person.
The group in the trial
- 1/[68Ga]Ga-PentixaFor PET/CT or PET/MRTreatment being tested
Participants will undergo \[68Ga\]Ga-PentixaFor PET/CT or PET/MR
Treatment: [68Ga]Ga-PentixaFor
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
- Plain-language title
- PET scan tracer to spot hormone-producing adrenal tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06246357, who can take part
- Record updated
- 22 October 2026